Interferon Gamma(Materia Medica Holding Research And Production Company)(Interferon Gamma(Materia Medica Holding Research And Production Company))

概要

基本信息

药物类型

干扰素

别名

Anaferon

靶点

IFNGR

作用方式

刺激剂

作用机制

IFNGR刺激剂(干扰素γ受体复合体刺激剂)、ADCC(抗体依赖的细胞毒作用)、免疫刺激剂

治疗领域

感染

在研适应症

细菌感染病毒感染

非在研适应症-

原研机构

Materia Medica Holding Research And Production Company

在研机构

Materia Medica Holding Research And Production Company

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 38628

来源: *****

关联

3

项与 Interferon Gamma(Materia Medica Holding Research And Production Company) 相关的临床试验

NCT03707912

/ Completed临床4期

Multicentre Double-blind Placebo-controlled Parallel Group Randomized Clinical Trial of Efficacy and Safety of Anaferon in the Treatment of Acute Respiratory Viral Infections

Purpose of the study:
• To obtain additional data on the efficacy and safety of Anaferon in the treatment of acute respiratory viral infections.

开始日期2018-10-09

申办/合作机构

OOO NPF Materia Medica Holding

NCT03301155

/ Completed临床4期

International Multicenter Double-bind Placebo-controlled Randomized Parallel-group Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other Acute Respiratory Viral Infections in Children During the Peaks of Seasonal Morbidity

The objective of this study is to obtain additional data on the efficacy and safety of 12-week course of therapy with Anaferon for children for prevention of influenza and other acute respiratory viral infections in children during the peaks of seasonal morbidity.

开始日期2017-10-03

申办/合作机构

OOO NPF Materia Medica Holding

NCT02072174

/ Completed临床4期

International Multicenter Double-blind Placebo-controlled Randomized Parallel Group Clinical Trial of Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children

The purpose of this study is:
• To obtain additional data on therapeutic efficacy of Anaferon for children in the treatment of influenza and acute respiratory viral infections in children

开始日期2014-10-08

申办/合作机构

OOO NPF Materia Medica Holding

100 项与 Interferon Gamma(Materia Medica Holding Research And Production Company) 相关的临床结果

登录后查看更多信息

100 项与 Interferon Gamma(Materia Medica Holding Research And Production Company) 相关的转化医学

登录后查看更多信息

100 项与 Interferon Gamma(Materia Medica Holding Research And Production Company) 相关的专利（医药）

登录后查看更多信息

23

项与 Interferon Gamma(Materia Medica Holding Research And Production Company) 相关的文献（医药）

2020-06-01·Immunology Letters4区 · 医学

The level of natural autoantibodies to IFN-gamma in varicella infection treated with antiviral drug Anaferon for children: A pilot study

4区 · 医学

Article

作者: van der Meide, Nathalie ; Don, Elena ; Tarasov, Sergey ; Putilovskiy, Mikhail ; Egorov, Valery

Natural circulating antibodies (NAbs) to endogenous regulators have shown to be potential biomarkers in medicine. Due to the lack of reliable assays, only few of them have been well studied. To employ NAbs as biomarkers, an evaluation of changes over the course of a treatment is required. This paper describes our work to analyze the dynamics of NAbs titer to interferon-gamma (IFN-γ) among healthy children of different age and in patients with varicella infection receiving an antiviral drug Anaferon for children (AC, the API are highly diluted antibodies to IFN-γ) in comparison with placebo, and to correlate the findings with the treatment results. IFN-γ plays an essential role during varicella infection, and this fact causes the consequent increase of NAbs to IFN-γ level. The mean anti-IFN-γ NAbs level in the healthy volunteer group was 101 × 10³ U/ml (age: 0-15 years), which was significantly lower than the mean pre-treatment value in patients with varicella infection 167 × 10³ U/ml (age: 3-17 years). In the AC group, the NAbs level observed on days 5 and 10 decreased significantly to a level of 154 × 10³ U/ml, whereas in the placebo group it continued to rise in a time-dependent manner reaching 229 × 10³ U/ml on day 10. Our findings suggest that treatment with AC is characterized by "normalization" of the anti-IFN-γ NAbs levels in patients with varicella infection.

2017-06-01·Antiviral Research2区 · 医学

RETRACTED: Efficacy of novel antibody-based drugs against rhinovirus infection: In vitro and in vivo results

2区 · 医学

Article

作者: Tarasov, Sergey A ; Emelyanova, Alexandra G ; Gogsadze, Leila ; Khaitov, Musa R ; Walton, Ross P ; Petrova, Nataliia V ; Edwards, Michael R ; Aniscenko, Julia ; Gorbunov, Evgeniy A ; Epstein, Oleg I ; Bakhsoliani, Eteri ; Johnston, Sebastian L ; Bartlett, Nathan W

Rhinoviruses (RVs) cause the common cold and are associated with exacerbations of chronic inflammatory respiratory diseases, especially asthma and chronic obstructive pulmonary disease (COPD). We have assessed the antiviral drugs Anaferon for Children (AC) and Ergoferon (containing AC as one of the active pharmaceutical ingredients) in in vitro and in vivo experimental models, in order to evaluate their anti-rhinoviral and immunomodulatory potential. HeLa cells were pretreated with AC, and levels of the interferon-stimulated gene (ISG), 2'-5'-oligoadenylate synthetase 1 (OAS1-A) and viral replication were analyzed. In a mouse model of RV-induced exacerbation of allergic airway inflammation we administered Ergoferon and analyzed its effect on type I (IFN-β), type II (IFN-γ) and type III (IFN-λ) IFNs induction, cell counts in bronchoalveolar lavage (BAL), cytokine (interleukin (IL)-4; IL-6) and chemokine (CXCL10/IP-10; CXCL1/KC) levels. It was shown that AC increased OAS1-А production and significantly decreased viral replication in vitro. Increased IFNs expression together with reduced neutrophils/lymphocytes recruitment and correlated IL-4/IL-6 declination was demonstrated for Ergoferon in vivo. However, there was no effect on examined chemokines. We conclude that AC and Ergoferon possess effects against RV infection and may have potential as novel therapies against RV-induced exacerbations of asthma.

2017-05-01·Journal of Medical Virology4区 · 医学

Dose-dependent antiviral activity of released-active form of antibodies to interferon-gamma against influenza A/California/07/09(H1N1) in murine model

4区 · 医学

Article

作者: Epstein, Оleg I. ; Don, Еlena S. ; Morozov, Sergey G. ; Petrova, Nataliia V. ; Gorbunov, Evgeniy A. ; Emelyanova, Alexandra G. ; Nikiforova, Marina V. ; Tarasov, Sergey А. ; Yakovleva, Natalia N.

The assessment of dose-response is an essential part of drug development in terms of the determination of a drug's effective dose, finding the safety endpoint, estimation of the pharmacokinetic profile, and even validation of drug activity, especially for therapeutic agents with a principally novel mechanism of action. Drugs based on released-active forms of antibodies are a good example of such a target. In this study, the efficacy of the antiviral drug Anaferon for children (released-active form of antibodies to interferon-gamma) was tested in a dose-dependent manner (at doses of 0.13, 0.2, 0.4, 0.8 ml/mouse/day) in a murine model of acute pneumonia induced by influenza virus pandemic strain A/California/07/09 (H1N1). Administration of the drug at the two highest doses led to: a reduction in the virus infectious titer in lung tissue up to 4.2 lgEID50/20 mg of tissue; infected animals' life prolongation up to 6.7 days; an increase in the survival rate of up to 40% and a decrease in morphological signs of inflammation when compared to the control animals. In this study, the dose-response effect of Anaferon for Children was demonstrated on mice for the first time. This finding is especially important for drugs with a principally novel mechanism of action like drugs based on released-active forms of antibodies. J. Med. Virol. 89:759-766, 2017. © 2016 Wiley Periodicals, Inc.

100 项与 Interferon Gamma(Materia Medica Holding Research And Production Company) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L03AB03	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
细菌感染	俄罗斯	Materia Medica Holding Research And Production Company	-
病毒感染	俄罗斯	Materia Medica Holding Research And Production Company	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03707912 (CTgov)	临床4期	急性呼吸道感染	204	Anaferon (Anaferon)	膚艱艱廠鹹憲簾廠顧獵(淵積製顧簾遞範鹹積鹹) = 醖願衊構顧願糧鑰衊淵簾範蓋網衊簾願顧獵簾 (衊艱製鹽醖鏇構糧選鹽, 選廠壓壓繭憲衊膚淵鏇 ~ 鹽齋鏇簾繭淵獵顧願衊) 更多	-	2020-09-02
				Placebo (Placebo)	膚艱艱廠鹹憲簾廠顧獵(淵積製顧簾遞範鹹積鹹) = 顧遞餘簾衊繭窪顧齋壓簾範蓋網衊簾願顧獵簾 (衊艱製鹽醖鏇構糧選鹽, 淵繭艱衊鏇膚衊鑰鏇窪 ~ 窪積鏇淵艱範製製觸觸) 更多
NCT03301155 (CTgov)	临床4期	病毒性呼吸道感染 \| 流感病毒感染	1,036	Anaferon (Anaferon for Children)	壓鹹鑰網鑰選鬱觸餘鏇(膚淵願艱鏇鬱顧醖積鹹) = 積範願齋憲憲淵顧選壓衊鏇淵齋蓋構壓醖鬱願 (壓衊鬱鏇鹽夢選窪艱衊, 壓壓鹽淵齋蓋齋襯觸遞 ~ 夢鹹鬱繭觸繭鬱繭廠鏇) 更多	-	2020-05-06
				Placebo (Placebo)	壓鹹鑰網鑰選鬱觸餘鏇(膚淵願艱鏇鬱顧醖積鹹) = 顧鏇構餘壓願遞網鏇構衊鏇淵齋蓋構壓醖鬱願 (壓衊鬱鏇鹽夢選窪艱衊, 齋範構鬱鹹廠膚壓壓齋 ~ 選窪選襯選壓齋壓壓鑰) 更多
NCT02072174 (CTgov)	临床4期	急性呼吸道感染 \| 病毒性呼吸道感染 \| 流感病毒感染	569	Anaferon for Children (Anaferon for Children)	鹽鏇網鏇願範憲艱網鹽(範醖獵顧壓構獵鹽觸鏇) = 夢糧網築膚膚鏇網獵願鏇獵齋醖憲鹽蓋廠壓鬱 (網窪築繭衊艱築窪壓顧, 顧膚壓餘築遞築獵鑰襯 ~ 壓鏇衊積鑰鏇鏇膚網餘) 更多	-	2019-07-12
				Anaferon for Children (Placebo)	鹽鏇網鏇願範憲艱網鹽(範醖獵顧壓構獵鹽觸鏇) = 鬱願獵製齋鏇憲醖簾壓鏇獵齋醖憲鹽蓋廠壓鬱 (網窪築繭衊艱築窪壓顧, 範膚鹽鏇網憲壓鹽構鏇 ~ 積製製膚築齋製憲醖夢) 更多